candesartan has been researched along with Cognition Disorders in 12 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
Excerpt | Relevance | Reference |
---|---|---|
"Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure." | 9.17 | Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013) |
"We investigated the effect of treatment of hypertension on cognition with the angiotensin-receptor-blocker, candesartan, in a placebo-controlled, double-blind, randomized controlled trial at one center participating in the Study on Cognition and Prognosis in the Elderly." | 9.13 | Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. ( Ford, GA; Harrington, F; McKeith, IG; Saxby, BK; Wesnes, KA, 2008) |
"Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure." | 5.17 | Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013) |
"One hundred and five patients eligible for coronary artery bypass graft surgery (65-85 years old, all suffering from hypertension and coronary artery disease, with stable kidney function) were randomized to candesartan (8 mg od) or placebo for between 8 and 11 days prior to surgery." | 5.14 | ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting. ( Erdmann, E; Flesch, M; Geissler, HJ; Kessler, G; Knipp, S; Massoudy, P; Philipp, T; Wilhelm, H, 2009) |
"We investigated the effect of treatment of hypertension on cognition with the angiotensin-receptor-blocker, candesartan, in a placebo-controlled, double-blind, randomized controlled trial at one center participating in the Study on Cognition and Prognosis in the Elderly." | 5.13 | Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. ( Ford, GA; Harrington, F; McKeith, IG; Saxby, BK; Wesnes, KA, 2008) |
"Treatment with candesartan markedly increased mRNA expression of angiotensin II type-2 receptor and methyl methanesulfonate sensitive-2 in the brain in KK-A(y) mice, determined by quantitative RT-PCR." | 1.34 | Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. ( Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (58.33) | 29.6817 |
2010's | 4 (33.33) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Kulisevsky, J | 1 |
Martínez-Horta, S | 1 |
Campolongo, A | 1 |
Pascual-Sedano, B | 1 |
Marín-Lahoz, J | 1 |
Bejr-Kasem, H | 1 |
Labandeira-Garcia, JL | 1 |
Lanciego, JL | 1 |
Puig-Davi, A | 1 |
Horta-Barba, A | 1 |
Pagonabarraga, J | 1 |
Rodríguez-Antigüedad, J | 1 |
Hornslien, AG | 1 |
Sandset, EC | 1 |
Bath, PM | 1 |
Wyller, TB | 1 |
Berge, E | 1 |
Li, Z | 1 |
Cao, Y | 1 |
Li, L | 1 |
Liang, Y | 1 |
Tian, X | 1 |
Mo, N | 1 |
Liu, Y | 1 |
Li, M | 1 |
Chui, D | 1 |
Guo, X | 1 |
Marchese, NA | 1 |
Artur de laVillarmois, E | 1 |
Basmadjian, OM | 1 |
Perez, MF | 1 |
Baiardi, G | 1 |
Bregonzio, C | 1 |
Flesch, M | 1 |
Knipp, S | 1 |
Kessler, G | 1 |
Geissler, HJ | 1 |
Massoudy, P | 1 |
Wilhelm, H | 1 |
Philipp, T | 1 |
Erdmann, E | 1 |
Hajjar, I | 1 |
Hart, M | 1 |
Chen, YL | 1 |
Mack, W | 1 |
Milberg, W | 1 |
Chui, H | 1 |
Lipsitz, L | 1 |
Sever, P | 1 |
Kumagai, H | 1 |
Onami, T | 1 |
Takimoto, C | 1 |
Iigaya, K | 1 |
Saruta, T | 1 |
Kim, S | 1 |
Kohara, K | 1 |
Tsukuda, K | 1 |
Mogi, M | 1 |
Li, JM | 1 |
Iwanami, J | 1 |
Min, LJ | 1 |
Sakata, A | 1 |
Fujita, T | 1 |
Iwai, M | 1 |
Horiuchi, M | 1 |
Saxby, BK | 1 |
Harrington, F | 1 |
Wesnes, KA | 1 |
McKeith, IG | 1 |
Ford, GA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Scandinavian Candesartan Acute Stroke Trial[NCT00120003] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)[NCT00605072] | Phase 2 | 53 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
This reports the change in the least square mean from baseline to 12 months, adjusted for age (NCT00605072)
Timeframe: Baseline-12 months
Intervention | cm/sec (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | -0.3 |
ARB (Candesartan) | -2.85 |
HCTZ | 0.35 |
Blood pressure was measured as follows: the participant was in the sitting position, rested for 5 minutes, no caffeine or smoking 2 hours prior to measurement, using appropriate cuff size (covering 60% of upper arm length and 80% of arm circumference), correct cuff placement (1-2 inches above brachial pulse on bare arm), and the bell of the stethoscope. The systolic blood pressure was defined as the pressure corresponding to the first korotkoff sounds (K1) and the diastolic as the pressure corresponding to the last korotkoff sound (K5). Blood pressure was measured in both arms and recorded (NCT00605072)
Timeframe: Baseline-12 months
Intervention | mm Hg (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | 28 |
ARB (Candesartan) | 27 |
HCTZ | 21 |
This test consists of series of digits of increasing length, some of which are recited as presented, and some of which are to be recited in reversed order. The forward digit span score ranges from 0 (ie cannot repeat two digits) to 8 ( participant can repeat up to 8 digits) (NCT00605072)
Timeframe: Baseline-12 months
Intervention | number of digits repeated (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | -0.3 |
ARB (Candesartan) | 0.02 |
HCTZ | -0.04 |
This is a 12-item list learning test in which individuals are presented three learning and recall trials followed by a delayed recall and 24 item recognition test. The HVLT-R has been identified as an ideal memory measure for elderly patients, and appropriate reliability and validity have been shown in older individuals. The test score is the number of correct answers in the delayed recall ( score range 0-12) (NCT00605072)
Timeframe: Baseline-12 months
Intervention | number words remembered (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | -1 |
ARB (Candesartan) | -2 |
HCTZ | -3 |
This test requires the connection of sequentially numbered circles (A), and the connection of circles marked by numbers and letters in alternating sequence (B). This test is considered a benchmark of executive function. The test score is the time required to complete the task in seconds. (NCT00605072)
Timeframe: Baseline-12 months
Intervention | seconds (Least Squares Mean) |
---|---|
ACEI (Lisinopril) | -14 |
ARB (Candesartan) | 17 |
HCTZ | 4 |
4 reviews available for candesartan and Cognition Disorders
Article | Year |
---|---|
The SCOPE trial. Study on Cognition and Prognosis in the Elderly.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Disorders; Humans; Hype | 2002 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
[Scope].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2004 |
[Study on cognition and prognosis in the elderly].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2006 |
6 trials available for candesartan and Cognition Disorders
Article | Year |
---|---|
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease.
Topics: Benzimidazoles; Cognition Disorders; Cognitive Dysfunction; Humans; Neuropsychological Tests; Parkin | 2023 |
Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Diso | 2013 |
ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2009 |
Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial.
Topics: Age Factors; Aged; Benzimidazoles; Biphenyl Compounds; Blood Pressure Determination; Cognition; Cogn | 2012 |
The SCOPE trial. Study on Cognition and Prognosis in the Elderly.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Disorders; Humans; Hype | 2002 |
Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Antihypertensive Age | 2008 |
3 other studies available for candesartan and Cognition Disorders
Article | Year |
---|---|
Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Ba | 2014 |
Brain Angiotensin II AT1 receptors are involved in the acute and long-term amphetamine-induced neurocognitive alterations.
Topics: Amphetamines; Angiotensin II Type 1 Receptor Blockers; Animals; Avoidance Learning; Behavior, Animal | 2016 |
Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2007 |